These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1139 related items for PubMed ID: 16636176

  • 1. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, McClure CD, Spinale FG, Zile MR.
    Circulation; 2006 May 02; 113(17):2089-96. PubMed ID: 16636176
    [Abstract] [Full Text] [Related]

  • 2. [Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure].
    Yang YJ, Zhang X, Zhu WL, Huang Y.
    Zhonghua Yi Xue Za Zhi; 2006 Jun 27; 86(24):1693-6. PubMed ID: 16854324
    [Abstract] [Full Text] [Related]

  • 3. Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function.
    Kosmala W, Plaksej R, Przewlocka-Kosmala M, Kuliczkowska-Plaksej J, Bednarek-Tupikowska G, Mazurek W.
    Int J Obes (Lond); 2008 May 27; 32(5):763-71. PubMed ID: 18197181
    [Abstract] [Full Text] [Related]

  • 4. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure.
    Wilson EM, Gunasinghe HR, Coker ML, Sprunger P, Lee-Jackson D, Bozkurt B, Deswal A, Mann DL, Spinale FG.
    J Card Fail; 2002 Dec 27; 8(6):390-8. PubMed ID: 12528092
    [Abstract] [Full Text] [Related]

  • 5. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
    George J, Patal S, Wexler D, Roth A, Sheps D, Keren G.
    Am Heart J; 2005 Sep 27; 150(3):484-7. PubMed ID: 16169329
    [Abstract] [Full Text] [Related]

  • 6. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
    Rysz J, Banach M, Stolarek RA, Pasnik J, Cialkowska-Rysz A, Koktysz R, Piechota M, Baj Z.
    J Nephrol; 2007 Sep 27; 20(4):444-52. PubMed ID: 17879211
    [Abstract] [Full Text] [Related]

  • 7. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
    Tayebjee MH, Nadar S, Blann AD, Gareth Beevers D, MacFadyen RJ, Lip GY.
    Am J Hypertens; 2004 Sep 27; 17(9):764-9. PubMed ID: 15363817
    [Abstract] [Full Text] [Related]

  • 8. Circulating matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases-1 and -2 levels in gestational hypertension.
    Tayebjee MH, Karalis I, Nadar SK, Beevers DG, MacFadyen RJ, Lip GY.
    Am J Hypertens; 2005 Mar 27; 18(3):325-9. PubMed ID: 15797648
    [Abstract] [Full Text] [Related]

  • 9. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart.
    Heymans S, Schroen B, Vermeersch P, Milting H, Gao F, Kassner A, Gillijns H, Herijgers P, Flameng W, Carmeliet P, Van de Werf F, Pinto YM, Janssens S.
    Circulation; 2005 Aug 23; 112(8):1136-44. PubMed ID: 16103240
    [Abstract] [Full Text] [Related]

  • 10. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling.
    Webb CS, Bonnema DD, Ahmed SH, Leonardi AH, McClure CD, Clark LL, Stroud RE, Corn WC, Finklea L, Zile MR, Spinale FG.
    Circulation; 2006 Sep 05; 114(10):1020-7. PubMed ID: 16923753
    [Abstract] [Full Text] [Related]

  • 11. Occurrence of matrix metalloproteinases and tissue inhibitors of metalloproteinases in tuberculous pleuritis.
    Hoheisel G, Sack U, Hui DS, Huse K, Chan KS, Chan KK, Hartwig K, Schuster E, Scholz GH, Schauer J.
    Tuberculosis (Edinb); 2001 Sep 05; 81(3):203-9. PubMed ID: 11466032
    [Abstract] [Full Text] [Related]

  • 12. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes].
    Florys B, Głowińska B, Urban M, Peczyńska J.
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006 Sep 05; 12(3):184-9. PubMed ID: 17020653
    [Abstract] [Full Text] [Related]

  • 13. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
    Kuyvenhoven JP, Molenaar IQ, Verspaget HW, Veldman MG, Palareti G, Legnani C, Moolenburgh SE, Terpstra OT, Lamers CB, van Hoek B, Porte RJ.
    Thromb Haemost; 2004 Mar 05; 91(3):506-13. PubMed ID: 14983226
    [Abstract] [Full Text] [Related]

  • 14. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension.
    Derosa G, D'Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S, Montagna L, Gravina A, Ferrari I, Galli S, Paniga S, Tinelli C, Cicero AF.
    Endothelium; 2006 Mar 05; 13(3):227-31. PubMed ID: 16840178
    [Abstract] [Full Text] [Related]

  • 15. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension.
    Tan J, Hua Q, Xing X, Wen J, Liu R, Yang Z.
    Hypertens Res; 2007 Oct 05; 30(10):959-63. PubMed ID: 18049028
    [Abstract] [Full Text] [Related]

  • 16. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents.
    Belo VA, Souza-Costa DC, Lana CM, Caputo FL, Marcaccini AM, Gerlach RF, Bastos MG, Tanus-Santos JE.
    Clin Biochem; 2009 Jul 05; 42(10-11):984-90. PubMed ID: 19358835
    [Abstract] [Full Text] [Related]

  • 17. Long-term effects of benidipine hydrochloride on severe left ventricular hypertrophy and collagen metabolism in patients with essential hypertension.
    Hirono O, Fatema K, Nitobe J, Takeishi Y, Kaneko K, Shiga R, Kubota I.
    J Cardiol; 2002 Apr 05; 39(4):195-204. PubMed ID: 11977767
    [Abstract] [Full Text] [Related]

  • 18. Cardiac remodeling and failure From molecules to man (Part II).
    Fedak PW, Verma S, Weisel RD, Li RK.
    Cardiovasc Pathol; 2005 Apr 05; 14(2):49-60. PubMed ID: 15780796
    [Abstract] [Full Text] [Related]

  • 19. Matrix metalloprotease activity is enhanced in the compensated but not in the decompensated phase of pressure overload hypertrophy.
    Tozzi R, Palladini G, Fallarini S, Nano R, Gatti C, Presotto C, Schiavone A, Micheletti R, Ferrari P, Fogari R, Perlini S.
    Am J Hypertens; 2007 Jun 05; 20(6):663-9. PubMed ID: 17531925
    [Abstract] [Full Text] [Related]

  • 20. Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis.
    Hoffmann U, Bertsch T, Dvortsak E, Liebetrau C, Lang S, Liebe V, Huhle G, Borggrefe M, Brueckmann M.
    Scand J Infect Dis; 2006 Jun 05; 38(10):867-72. PubMed ID: 17008230
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.